Available Technologies
# of Displayed Technologies: 5 / 5
Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
- College: OSU Wexner Medical Center
- Inventors:
- Licensing Officer: Schultz, Teri
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College of Medicine (COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Schultz, Teri
Revolutionizing Vascular Access Management for Hemodialysis Patients
TS-062693 — Dynamic AVF flow control: A paradigm shift in vascular access management for hemodialysis patients.
Patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) face critical challenges in maintaining functional vascular access. Despite the superiority of arteriovenous fistulas (AVFs) in terms of longevity, infection rates, and cost-effectiveness, over a third of AVFs fail to mature a…
- College: College of Medicine (COM)
- Inventors: Boobes, Khaled
- Licensing Officer: Schultz, Teri
Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
- College: College of Medicine (COM)
- Inventors: Chu, Nam; Le, Nhat
- Licensing Officer: Willson, Christopher
Revolutionizing Cancer Research: Unveiling the Dynamics of K-Ras for Targeted Therapies
TS-062433 — The Need: Understanding the intricate functions of the K-Ras protein is crucial in combating various types of human cancer. However, the lack of detailed atomic-level information has hindered progress in this area, leaving significant gaps in our comprehension of its roles in health and disease.
Th…
- College: Enterprise for Research, Innovation and Knowledge (ERIK)
- Inventors: Bruschweiler, Rafael; Bruschweiler-Li, Lei "Lei"; Hansen, Alexandar "Alex"; Xiang, Xinyao; Yuan, Chunhua
- Licensing Officer: Dahlman, Jason "Jay"
